Funds and ETFs Zhejiang Starry Pharmaceutical Co.,Ltd.

603520

CNE1000026N8

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
11.87 ^CNY	+0.17%		+9.00%	-15.70%

2023	Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	CI
2023	Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	CI

ETFs positioned on Zhejiang Starry Pharmaceutical Co.,Ltd.

Name	Weight	AuM	1st Jan change	Investor Rating
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD	0.00%	34 M€	+2.14%	-

Zhejiang Starry Pharmaceutical Co., Ltd. is principally engaged in the research and development (R&D), production and sales of X-ray contrast medium, quinolone antimicrobial agents and other drugs' pharmaceutical raw materials and intermediates. The X-ray contrast medium's major product is iohexol active pharmaceutical ingredient. Quinolone antimicrobial agents' major products are levofloxacin hydrochloride active pharmaceutical ingredient and levofloxacin hemihydrates active pharmaceutical ingredient.

Sector

Pharmaceuticals

Calendar

2024-04-29 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Zhejiang Starry Pharmaceutical Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.87

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD.	-15.70%	561M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B